<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036554</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001AKR11T</org_study_id>
    <nct_id>NCT02036554</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in&#xD;
      comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset&#xD;
      Diabetes Mellitus after transplantation in the renal allograft recipients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, multi-center, comparative parallel study to evaluate prevention&#xD;
      effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with&#xD;
      standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus&#xD;
      after transplantation in the renal allograft recipients: PROTECT study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months</measure>
    <time_frame>0 to 12 month</time_frame>
    <description>To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation at 12 months after date of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance by HOMA-IR</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Change from Baseline(V2) in Insulin resistance by HOMA-IR at 12months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion by HOMA-beta</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Change from Baseline(V2) in insulin secretion by HOMA-beta at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT (Fasting and PP2hr)</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Change from baseline in OGTT (Fasting and PP2hr) at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needs for anti-diabetic medication or insulin at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Needs for anti-diabetic medication or insulin at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance (MDRD eGFR) at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Creatinine clearance (MDRD eGFR) at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 month graft survival</measure>
    <time_frame>at 12 months(V6)</time_frame>
    <description>After date of randomization, evaluate graft survival rate at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 month patient survival rate</measure>
    <time_frame>at 12 months(V6)</time_frame>
    <description>After date of randomization, evaluate patient survival rate at 12 months(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Microalbuminuria(MAU) at 12 months</measure>
    <time_frame>at 12 months(V6)</time_frame>
    <description>Change from baseline in Microalbuminuria(MAU) at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episode of biopsy proven acute rejection (BPAR)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Cumulative incidence rate of Biopsy Proven Acute Rejection(BPAR) at 12months(V6) after date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5)</measure>
    <time_frame>at 9 month(V5)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of opportunistic infections (BKVN) at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Number of opportunistic infections (BKVN) at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of opportunistic infections (BKVN) at 12month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Number of opportunistic infections (BKVN) at 12month(V6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at Baseline(V2)</measure>
    <time_frame>at Baseline(V2)</time_frame>
    <description>Prevalence of NODAT at Baseline(V2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 3 month(V3)</measure>
    <time_frame>at 3 month(V3)</time_frame>
    <description>Prevalence of NODAT at 3 month(V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 6 month(V4)</measure>
    <time_frame>at 6 month(V4)</time_frame>
    <description>Prevalence of NODAT at 6 month(V4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 9 month (V5)</measure>
    <time_frame>at 9 month (V5)</time_frame>
    <description>Prevalence of NODAT at 9 month (V5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NODAT at 12 month(V6)</measure>
    <time_frame>at 12 month(V6)</time_frame>
    <description>Prevalence of NODAT at 12 month(V6)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Kidney; Complications, Allograft</condition>
  <arm_group>
    <arm_group_label>Tacrolimus plus Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Tacrolimus + Everolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus plus Mycophenolic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard dose Tacrolimus + Mycophenolic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.</description>
    <arm_group_label>Tacrolimus plus Everolimus</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.</description>
    <arm_group_label>Tacrolimus plus Everolimus</arm_group_label>
    <arm_group_label>Tacrolimus plus Mycophenolic acid</arm_group_label>
    <other_name>Tacroli</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid</intervention_name>
    <description>Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.</description>
    <arm_group_label>Tacrolimus plus Mycophenolic acid</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 20 year old&#xD;
&#xD;
          2. At least 3 months after kidney transplantation&#xD;
&#xD;
          3. Subject who is using Tacrolimus ± purine synthesis inhibitor + steroid without change&#xD;
             within the past 3 months (except the dosage)&#xD;
&#xD;
          4. MDRD eGFR ≥ 50 mL/min or serum creatinine &lt; 2.0mg/dL within the past 3 months in the&#xD;
             6months after kidney transplantation&#xD;
&#xD;
          5. Rate of change of serum creatinine &lt; +30% within the past 3 months in the 6months&#xD;
             after kidney transplantation (if serum creatinine decreased, without rate of change is&#xD;
             inclusion possible. if serum creatinine result was normal,regardless of the rate of&#xD;
             change is able to register.)&#xD;
&#xD;
          6. Urine protein/creatinine ratio &lt; 1g/g Cr (spot urine) Subject who is not applicable to&#xD;
             the diagnostic criteria NODAT on&#xD;
&#xD;
          7. the baseline in the 6months after kidney transplantation&#xD;
&#xD;
          8. Subjects who agree with written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who received combined non-renal transplantation&#xD;
&#xD;
          2. Subject who received re-transplantation&#xD;
&#xD;
          3. ABO blood group incompatible(when anti-ABO Antibody titer &lt;1:128 is inclusion&#xD;
             possible.)&#xD;
&#xD;
          4. Sensitized patients before transplantation&#xD;
&#xD;
               -  Pretransplant or peak PRA titer &gt; 50%&#xD;
&#xD;
               -  Pretransplant T cell cytotoxicity crossmatch (+)&#xD;
&#xD;
          5. HLA-identical living related donor&#xD;
&#xD;
          6. Subject who has diabetes mellitus / NODAT before transplantation&#xD;
&#xD;
          7. Subject who has suffered acute rejection episode within the past 3 months in the&#xD;
             6months after kidney transplantation&#xD;
&#xD;
          8. Subject with hypersensitivity to everolimus&#xD;
&#xD;
          9. Subject who should continue nephrotoxic drug until enrollment (Aminoglycoside,&#xD;
             amphotericin B, cisplatin)&#xD;
&#xD;
         10. Subject with GI disorder that might interfere with the ability to absorb oral&#xD;
             medication. (eg, gastrectomy or insufficiently treated diabetic gastroenteropathy)&#xD;
&#xD;
         11. Subjects with active peptic ulcer&#xD;
&#xD;
         12. HIV, HBsAg, or HCV Ab tests (+)&#xD;
&#xD;
         13. Abnormal liver function test (AST or ALT or total bilirubin&gt; upper normal limit x3)&#xD;
&#xD;
         14. ANC &lt;1.5*109/L or WBC &lt;2.5*109/L or platelet &lt;75*109/L&#xD;
&#xD;
         15. Treatment with an investigational drug within 30 days preceding the first dose of&#xD;
             trial medication&#xD;
&#xD;
         16. Women who are either pregnant, lactating, planning to become pregnant in the next 12&#xD;
             months.&#xD;
&#xD;
         17. Subjects with history of cancer(except successfully treated), localized nonmelanocytic&#xD;
             skin cancer, PTLD(Post-transplant lymphoproliferative disorder)&#xD;
&#xD;
         18. Subjects with clinically significant infections within the past 4 weeks in the 6months&#xD;
             after kidney transplantation&#xD;
&#xD;
         19. Subjects who took major surgery within the past 4 weeks in the 6months after kidney&#xD;
             transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Woo Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Mary's Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>division of nephrology;Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chul Woo Yang</last_name>
      <phone>82-2-2258-6851</phone>
      <email>yangch@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>ChulWoo Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

